Trial Profile
Observational post-marketing registry exploring the safety and efficacy of the COMBO stent in an all-comer percutaneous coronary intervention (PCI) cohort
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 Oct 2017
Price :
$35
*
At a glance
- Drugs Anti-CD34 monoclonal antibody/sirolimus (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions
- Acronyms MASCOT
- 31 Oct 2017 New trial record
- 23 Oct 2017 According to an OrbusNeich media release, data will be presented at the 29th Transcatheter Cardiovascular Therapeutics (TCT).